Targeted small molecule therapy and inhibitors for lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lymphoma is the ninth most common cancer globally as of 2020.
• Targeted inhibition represents a key therapeutic strategy for lymphoma treatment.
• Histone deacetylase (HDAC), Bruton's tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K) are crucial in tumor development and are promising targets.

Purpose of the Study:

• To review the role of HDAC, BTK, and PI3K in tumorigenesis.
• To discuss the mechanism of action, structure-activity relationships, and clinical research of small molecule inhibitors targeting these proteins.
• To offer novel therapeutic insights for lymphoma treatment.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of the molecular mechanisms of targeted inhibitors.
• Synthesis of structure-activity relationship data for small molecule inhibitors.

Main Results:

• HDAC, BTK, and PI3K are validated targets in various cancers, including lymphoma.
• Several small molecule inhibitors targeting these pathways have demonstrated efficacy and safety in clinical studies.
• Understanding structure-activity relationships aids in the development of more potent and selective inhibitors.

Conclusions:

• Targeted inhibition of HDAC, BTK, and PI3K offers a promising avenue for lymphoma treatment.
• Continued research into small molecule inhibitors is essential for advancing lymphoma therapy.
• This review provides a foundation for developing new treatment strategies for lymphoma.